Search results for "antihypertensive agents"

showing 10 items of 184 documents

Novel Antihypertensive Lactoferrin-Derived Peptides Produced by Kluyveromyces marxianus: Gastrointestinal Stability Profile and In Vivo Angiotensin I…

2014

Novel antihypertensive peptides released by Kluyveromyces marxianus from bovine lactoferrin (LF) have been identified. K. marxianus LF permeate was fractionated by semipreparative high performance liquid chromatography and 35 peptides contained in the angiotensin I-converting enzyme (ACE)-inhibitory fractions were identified by using an ion trap mass spectrometer. On the basis of peptide abundance and common structural features, six peptides were chemically synthesized. Four of them (DPYKLRP, PYKLRP, YKLRP, and GILRP) exerted in vitro inhibitory effects on ACE activity and effectively decreased systolic blood pressure after oral administration to spontaneously hypertensive rats (SHRs). Stab…

MaleAntihypertensive effectsAdministration OralAngiotensin-Converting Enzyme InhibitorsBlood PressurePeptideLactoferrin-derived peptidesPeptidyl-Dipeptidase AKluyveromycesKluyveromyces marxianusIn vivoRats Inbred SHRRenin–angiotensin systemAnimalsHumansKluyveromyces marxianusAmino Acid SequencePeptide sequenceAntihypertensive AgentsBiotransformationchemistry.chemical_classificationbiologyLactoferrinGastrointestinal digestionGeneral Chemistrybiology.organism_classificationAngiotensin IIRatsLactoferrinEnzymeBiochemistrychemistryHypertensionbiology.proteinCattlePeptidesGeneral Agricultural and Biological SciencesIn vivo ACE inhibition
researchProduct

Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats

2009

International audience; Among their pleiotropic effects, statins exert antioxidant and anti-inflammatory properties. The aim of this study was to evaluate in normotensive (WKY) and in spontaneously hypertensive rats (SHR) the effect of rosuvastatin (ROSU) treatment on (1) plasma inflammation markers and endogenous NO synthase inhibitor (ADMA) levels, (2) reactive oxygen species (ROS) generated by circulating leukocytes and (3) vascular oxidative stress and tissue inflammation markers. Plasma cytokines were higher in SHR than in WKY, except for IL-4, which was lower in SHR than in WKY. SHR monocytes exhibited higher production of ROS than did WKY monocytes. In the experimental conditions, RO…

MaleAntioxidantmedicine.medical_treatmentBlood Pressure030204 cardiovascular system & hematologymedicine.disease_causeBiochemistryRats Inbred WKYchemistry.chemical_compound0302 clinical medicineRats Inbred SHR[SDV.IDA]Life Sciences [q-bio]/Food engineeringRosuvastatin CalciumComputingMilieux_MISCELLANEOUSchemistry.chemical_classification0303 health sciencesSulfonamidesGeneral Medicine3. Good healthNAD(P)H oxidasecardiovascular systemmedicine.symptommedicine.drugmedicine.medical_specialtyhypertensionleukocytesInflammationArgininestatins03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineAnimalsRosuvastatin[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process Engineeringcardiovascular diseasesAntihypertensive Agents030304 developmental biologyInflammationReactive oxygen speciesCholesterolNAD(P)H oxidaseNADPH OxidasescytokinesRatsFluorobenzenesOxidative StressEndocrinologyBlood pressurePyrimidineschemistryInterleukin-4Hydroxymethylglutaryl-CoA Reductase InhibitorsReactive Oxygen SpeciesOxidative stress
researchProduct

May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension.

2019

Abstract Aims Raised blood pressure (BP) is the biggest contributor to mortality and disease burden worldwide and fewer than half of those with hypertension are aware of it. May Measurement Month (MMM) is a global campaign set up in 2017, to raise awareness of high BP and as a pragmatic solution to a lack of formal screening worldwide. The 2018 campaign was expanded, aiming to include more participants and countries. Methods and results Eighty-nine countries participated in MMM 2018. Volunteers (≥18 years) were recruited through opportunistic sampling at a variety of screening sites. Each participant had three BP measurements and completed a questionnaire on demographic, lifestyle, and envi…

MaleCardiac & Cardiovascular SystemsCross-sectional studyBlood Pressure030204 cardiovascular system & hematologyGlobal Burden of Disease0302 clinical medicineSurveys and QuestionnairesMMM InvestigatorsMass Screening030212 general & internal medicine1102 Cardiorespiratory Medicine and HaematologyAntihypertensive medicationRISKGlobalAwarenessMiddle AgedPREVALENCEHypertensionBlood pressureScreeningRaised blood pressureFemaleCardiology and Cardiovascular MedicineBURDENLife Sciences & BiomedicineControl; GlobalAdultmedicine.medical_specialtyFast Track Clinical ResearchOpportunistic Sampling03 medical and health sciencesInternal medicineControlmedicineSYSTEMATIC ANALYSISMANAGEMENTHumansMass screeningDisease burdenAntihypertensive AgentsScience & Technologybusiness.industryCase-control studyBlood Pressure DeterminationTreatmentEditor's ChoiceBlood pressureRAMADANCross-Sectional StudiesCardiovascular System & HematologyCase-Control StudiesCardiovascular System & CardiologybusinessHypertension Blood pressure Screening Global Treatment ControlEuropean heart journal
researchProduct

Effects of Fenoldopam on Intracranial Pressure and Hemodynamic Variables at Normal and Elevated Intracranial Pressure in Anesthetized Pigs

1994

Fenoldopam (FE), a dopamine DA1-receptor agonist, has been introduced for treatment of arterial hypertension and heart failure and for preservation of renal function. Vasodilators are generally assumed to affect all vascular beds including the cerebral circulation. We have evaluated effects of FE-induced (4 micrograms.kg-1.min-1) arterial hypotension on intracranial pressure (ICP) and intraocular pressure (IOP) under conditions of normal and increased intracranial elastance. ICP and IOP responses to hypertension were tested by infusion of angiotensin II (15 micrograms.kg-1.min-1), and the response to hypercapnia was tested by elimination and reintegration of soda lime canisters in the breat…

MaleCentral Venous PressureIntracranial PressureFenoldopamSwineDopamine AgentsHemodynamicsBlood PressureAnesthesia GeneralFenoldopamCerebral autoregulationHypercapniaCerebral circulationCerebrospinal fluidHeart RateAnimalsMedicinePulmonary Wedge PressureAntihypertensive AgentsIntraocular PressureIntracranial pressurePseudotumor CerebriDose-Response Relationship Drugbusiness.industryAngiotensin IIHemodynamicsAngiotensin IIAnesthesiology and Pain MedicineCerebrovascular CirculationAnesthesiaHypertensionFemaleOcular HypertensionVascular ResistanceSurgery2345-Tetrahydro-78-dihydroxy-1-phenyl-1H-3-benzazepineNeurology (clinical)medicine.symptombusinessHypercapniamedicine.drugJournal of Neurosurgical Anesthesiology
researchProduct

Patients with coronary artery disease and diabetes need improved management : a report from the EUROASPIRE IV survey: a registry from the EuroObserva…

2015

Background: In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines. Methods: A total of 6187 patients (18-80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabet…

MaleEUROASPIRE InvestigatorsCardiac & Cardiovascular SystemsCross-sectional studyEndocrinology Diabetes and MetabolismAngiotensin-Converting Enzyme InhibitorsBlood PressureCoronary Artery DiseaseType 2 diabetesGUIDELINESCoronary artery diseaseMELLITUSRisk FactorsGlycaemic controlMedicine and Health SciencesSecondary PreventionCoronary artery disease ; Type 2 diabetes ; Secondary prevention ; Management ; Guideline adherence ; Blood lipids ; Blood pressure ; Glycaemic controlCardiac and Cardiovascular SystemsRegistriesMyocardial infarctionGLUCOSE CONTROLOriginal InvestigationBLOOD-GLUCOSEType 2 diabetesMiddle AgedManagementEuropeglycaemic controlHypertensionPractice Guidelines as TopicHEARTPlatelet aggregation inhibitorFemaletype 2 diabetesGuideline AdherenceCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemanagementmedicine.medical_specialtyCardiotonic AgentsAdrenergic beta-Antagonists/Endocrinology and Diabetes1102 Cardiovascular Medicine And HaematologyEndocrinology & MetabolismAngiotensin Receptor AntagonistsSDG 3 - Good Health and Well-beingInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentsddc:610Risk factorAntihypertensive AgentsAgedDyslipidemiasScience & Technologyblood lipidsbusiness.industryMORTALITYCholesterol LDLmedicine.diseaseCross-Sectional StudiesBlood pressureCardiovascular System & HematologyMYOCARDIAL-INFARCTIONDiabetes Mellitus Type 2Cardiovascular System & CardiologyBlood lipidsCARDIOVASCULAR-DISEASESRISK-FACTORSHydroxymethylglutaryl-CoA Reductase InhibitorsFOLLOW-UPbusinessPlatelet Aggregation Inhibitors
researchProduct

An Expert Opinion From the European Society of Hypertension–European Union Geriatric Medicine Society Working Group on the Management of Hypertension…

2016

Two years after the publication of the 2013 guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC),1 the ESH and the European Union Geriatric Medicine Society have created a common working group to examine the management of hypertensive subjects aged >80 years. The general term hypertension in the elderly is not sufficiently accurate because it mixes younger old patients (60–70 years) with the oldest old. Our group believes that the management of hypertension in individuals aged ≥80 years should be specifically addressed. Although arbitrary, this cutoff value identifies a population that is expanding …

MaleGerontologyBLOOD-PRESSUREL-ARGININE TRANSPORTFAT-FED RABBITS030204 cardiovascular system & hematologySeverity of Illness IndexSYMPATHETIC-NERVE ACTIVITY0302 clinical medicine80 and overPerindopril030212 general & internal medicineDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUSMETABOLIC SYNDROMEmedia_commonAged 80 and overGeriatricseducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyIndapamideDisease ManagementPrognosis[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthAntihypertensive AgentTreatment OutcomeHypertensionPractice Guidelines as TopicFemaleSurvival AnalysiHumanmedicine.drugANGIOTENSIN-CONVERTING ENZYMEmedicine.medical_specialtyPrognosiFrail ElderlyeducationPopulationRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMedicalInternal MedicinemedicineHumansmedia_common.cataloged_instanceEuropean UnionNITRIC-OXIDE SYNTHASEEuropean unioneducationREDUCES OXIDATIVE STRESSExpert TestimonyGeriatric AssessmentAntihypertensive AgentsAgedAged; Aged 80 and over; Antihypertensive Agents; Blood Pressure Determination; Disease Management; European Union; Expert Testimony; Female; Frail Elderly; Geriatric Assessment; Geriatrics; Humans; Hypertension; Male; Prognosis; Risk Assessment; Severity of Illness Index; Societies Medical; Survival Analysis; Treatment Outcome; Practice Guidelines as Topic; Internal Medicinebusiness.industryBlood Pressure DeterminationSurvival AnalysisBlood pressureOBESITY-INDUCED HYPERTENSIONGeriatrics3121 General medicine internal medicine and other clinical medicineENDOTHELIAL DYSFUNCTIONLife expectancySocietiesbusinessGeriatric[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHypertension
researchProduct

Meta-Analysis of Articles Evaluating Routine Intraocular Pressure Control in Monotherapy in the United States and Germany

2009

Pur P ose . To evaluate routine intraocular pressure (IOP) control in monotherapy patients in the United States and Germany. Methods . Meta-analysis of published articles. We included articles that were prospective studies of ocular hypotensive therapies that measured an unaltered (visit 1) IOP on monotherapy before enrolling into a clinical trial. results . This meta-analysis included 5 studies with 7913 patients, of whom 3245 were from the United States (n=1) and 4668 were from Germany (n=4). In the United States, 2939 patients (91%), and in Germany, 4059 patients (87%), had glaucoma (p<0.0001). Of these, all the US patients (100%) and 2694 (58%) of those from Germany were treated with mo…

MaleIntraocular pressurePediatricsmedicine.medical_specialtyGlaucomaTreatment goals03 medical and health sciences0302 clinical medicineGermanymedicineHumansProspective cohort studyAntihypertensive AgentsIntraocular PressureAgedbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseUnited StatesClinical trialOphthalmologyMeta-analysisLower pressure030221 ophthalmology & optometryFemaleOcular HypertensionbusinessGlaucoma Open-Angle030217 neurology & neurosurgeryEuropean Journal of Ophthalmology
researchProduct

A Randomized Trial of a Schlemm's Canal Microstent with Phacoemulsification for Reducing Intraocular Pressure in Open-Angle Glaucoma

2014

Purpose To assess the safety and effectiveness of the Hydrus Microstent (Ivantis, Inc, Irvine, CA) with concurrent cataract surgery (CS) for reducing intraocular pressure (IOP) in open-angle glaucoma (OAG). Design Prospective, multicenter, randomized, single-masked, controlled clinical trial. Participants One hundred eyes from 100 patients 21 to 80 years of age with OAG and cataract with IOP of 24 mmHg or less with 4 or fewer hypotensive medications and a washed-out diurnal IOP (DIOP) of 21 to 36 mmHg. Methods On the day of surgery, patients were randomized 1:1 to undergo CS with the microstent or CS alone. Postoperative follow-up was at 1 day, 1 week, and 1, 3, 6, 12, 18, and 24 months. Wa…

MaleIntraocular pressureVisual acuityMinimally invasive glaucoma surgerymedicine.medical_treatmentVisual AcuityGlaucomalaw.inventionRandomized controlled trialLens Implantation Intraocularlaw80 and overMedicineSingle-Blind MethodProspective StudiesProspective cohort studyGlaucoma Drainage ImplantsAged 80 and overIntraocularMedicine (all)Adult; Aged; Aged 80 and over; Antihypertensive Agents; Female; Follow-Up Studies; Glaucoma Open-Angle; Humans; Intraocular Pressure; Lens Implantation Intraocular; Limbus Corneae; Male; Middle Aged; Prospective Studies; Prosthesis Implantation; Single-Blind Method; Tonometry Ocular; Visual Acuity; Visual Fields; Young Adult; Glaucoma Drainage Implants; Phacoemulsification; Stents; Ophthalmology; Medicine (all)Middle AgedOpen-AngleFemaleStentsmedicine.symptomLens ImplantationGlaucoma Open-AngleAdultmedicine.medical_specialtyLimbus CorneaeTonometryProsthesis ImplantationTonometry OcularYoung AdultOphthalmologyOcularHumansAntihypertensive AgentsIntraocular PressureAgedPhacoemulsificationbusiness.industryGlaucomaPhacoemulsificationCataract surgerymedicine.diseaseOphthalmologyVisual FieldsbusinessFollow-Up Studies
researchProduct

Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocul…

2019

UNLABELLED: PRéCIS:: Noninferiority of efficacy was demonstrated for a preservative-free latanoprost-timolol fixed combination compared with a BAK-containing formulation at 84 days after treatment in patients with open-angle glaucoma or ocular hypertension. PURPOSE: The purpose of this study was to compare the effect on intraocular pressure and safety of preservative-free latanoprost-timolol fixed combination (T2347) to benzalkonium chloride-preserved latanoprost-timolol fixed combination in patients with open-angle glaucoma or ocular hypertension. METHODS: Phase III, randomized, parallel-group, investigator-masked study in 10 countries. A total of 242 patients aged 18 years or older with o…

MaleIntraocular pressuregenetic structures:Ciencias de la Salud::Oftalmología [Materias Investigacion]Ocular hypertensionGlaucomaLatanoprost-timololT2347 Study GroupOcular hypertensionlaw.invention0302 clinical medicineRandomized controlled triallawAged 80 and overMiddle AgedDrug CombinationsTreatment OutcomeTimololLatanoprostFemalemedicine.symptomLatanoprost/timololBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugAdultmedicine.medical_specialtyOpen angle glaucomaEquivalence Trials as Topic03 medical and health sciencesTonometry OcularOphthalmologymedicineHumansPreservative-freeAdverse effectAntihypertensive AgentsIntraocular PressureAgedbusiness.industryPreservatives PharmaceuticalGlaucomamedicine.diseaseeye diseasesOphthalmology030221 ophthalmology & optometryItchingOcular Hypertensionsense organsOphthalmic Solutionsbusiness030217 neurology & neurosurgery
researchProduct

Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolam…

2017

Introduction To demonstrate that preoperative treatment for 28 days with topical dorzolamide/timolol is non-inferior (Δ = 4 mm Hg) to oral acetazolamide and topical dexamethasone (standard therapy) in terms of intraocular pressure (IOP) reduction 3 and 6 months after trabeculectomy in glaucoma patients. Materials and methods Sixty-two eyes undergoing trabeculectomy with mitomycin C were included in this monocentric prospective randomized controlled study. IOP change between baseline and 3 months post-op was defined as the primary efficacy variable. Secondary efficacy variables included the number of 5-fluorouracil (5-FU) injections, needlings, suture lyses, preoperative IOP change, hyperten…

MaleIntraocular pressuregenetic structuresEye DiseasesPhysiologymedicine.medical_treatmentTimololGlaucomalcsh:Medicine030204 cardiovascular system & hematologyDexamethasone0302 clinical medicineGlaucoma surgeryMedicine and Health SciencesMedicineTrabeculectomyProspective Studieslcsh:ScienceSulfonamidesMultidisciplinaryPharmaceuticsDorzolamide/TimololOphthalmic ProceduresMiddle AgedDrug CombinationsTreatment OutcomeResearch DesignAnesthesiaTimololFemaleFluorouracilAnatomyAcetazolamidemedicine.drugResearch Articlemedicine.medical_specialtyLysis (Medicine)Clinical Research DesignSurgical and Invasive Medical ProceduresTrabeculectomyThiophenesResearch and Analysis Methods03 medical and health sciencesMusculoskeletal System ProceduresDorzolamideDrug TherapyOcular SystemOphthalmologyTissue RepairPreoperative CareHumansAntihypertensive AgentsIntraocular PressureAgedbusiness.industrylcsh:RBiology and Life SciencesGlaucomamedicine.diseaseeye diseasesAcetazolamideOphthalmology030221 ophthalmology & optometryEyeslcsh:QOcular Hypertensionsense organsAdverse EventsOphthalmic SolutionsbusinessPhysiological ProcessesHeadPLoS ONE
researchProduct